NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:YMAB), a late-stage clinical biopharmaceutical company focused on the development and ...

Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study One hundred two patients with ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Y-mAbs Therapeutics has experienced a significant recovery in value but lacks upcoming catalysts for near-term growth. Their approved therapy, naxitamab, has shown promising results in treating ...

Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases Patients enrolled onto NCT00072358 received ...

At the San Antonio Breast Cancer Symposium, Margaret Gatti-Mays, MD, MPH, of the Ohio State University in Columbus, discussed the ongoing phase Ib/II DiG NKs trial, which is assessing gemcitabine, ...

Y-mAbs announces GD2-SADA clinical trial presentation for treating GD2-expressing tumors at the Advances in Neuroblastoma Research Meeting. Y-mAbs Therapeutics, Inc. has announced the presentation of ...

Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data ...

CHICAGO — An experimental monoclonal antibody has demonstrated promising results in neuroblastoma, according to new findings. In an interim analysis, 80% of newly diagnosed, young, high-risk patients ...

YMAB's naxitamab sales declined from Q3 2023 to Q3 2024, but the company has a strong cash runway, supporting operations until 2027. Upcoming data readouts for GD2-SADA in Q2 2025 are critical for ...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today shared updates on the company’s oncology pipeline and focused approach to the research and development of ...